AZN 250509 70.00P(AZN250509P70000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

AZN250509P70000

Watchlist

2.54
+2.18+605.56%

15min DelayClose May 8 16:00 ET

2.54High2.25Low

Intraday

5D
Daily

News

Top Gap Ups and Downs on Thursday: AZN, MELI, APP and More
Moomoo News18:00 ET · Markets
Unusual Options Activity: MSTR, TECK and Others Attract Market Bets, MSTR V/OI Ratio Reaches 136.4
Moomoo News16:30 ET
AstraZeneca Call Volume Above Normal and Directionally Bullish
TipRanks15:31 ET
FDA to Speed up AI Rollout to Accelerate Drug Reviews
Seeking Alpha14:53 ET
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
MT NewswiresMay 8 11:19 ET
Trump Says U.K. Trade Deal Is First of Many. It Will Only Get Harde
Barron'sMay 8 09:12 ET

Comments

The World’s ATM

$AstraZeneca (AZN.US)$ should not buy u. all vaccine also banned next time.

1

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy

$AstraZeneca (AZN.US)$
First Major Breakthrough in 10 Years: ENHERTU Combo Outperforms Standard HER2+ Breast Cancer Treatment

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Posit

$AstraZeneca (AZN.US)$
First Major Breast Cancer Treatment Breakthrough in 10 Years: ENHERTU Trial Reveals Superior Efficacy

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Posit

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

$AstraZeneca (AZN.US)$
Revolutionary AI Technology Detects Lung Cancer Mutations Without Invasive Testing

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

$AstraZeneca (AZN.US)$
New Breast Cancer Drug DATROWAY Shows 37% Better Survival Rates in EU Approval

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Read more